Logo image of APLT

APPLIED THERAPEUTICS INC (APLT) Stock Fundamental Analysis

NASDAQ:APLT - Nasdaq - US03828A1016 - Common Stock - Currency: USD

0.4139  0 (-0.05%)

After market: 0.404 -0.01 (-2.39%)

Fundamental Rating

2

Overall APLT gets a fundamental rating of 2 out of 10. We evaluated APLT against 560 industry peers in the Biotechnology industry. While APLT seems to be doing ok healthwise, there are quite some concerns on its profitability. APLT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year APLT has reported negative net income.
APLT had a negative operating cash flow in the past year.
In the past 5 years APLT always reported negative net income.
In the past 5 years APLT always reported negative operating cash flow.
APLT Yearly Net Income VS EBIT VS OCF VS FCFAPLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

APLT's Return On Assets of -76.46% is on the low side compared to the rest of the industry. APLT is outperformed by 67.44% of its industry peers.
APLT has a Return On Equity (-118.66%) which is in line with its industry peers.
Industry RankSector Rank
ROA -76.46%
ROE -118.66%
ROIC N/A
ROA(3y)-185.04%
ROA(5y)-152.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APLT Yearly ROA, ROE, ROICAPLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K -2K

1.3 Margins

APLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APLT Yearly Profit, Operating, Gross MarginsAPLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

5

2. Health

2.1 Basic Checks

APLT has more shares outstanding than it did 1 year ago.
APLT has more shares outstanding than it did 5 years ago.
APLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APLT Yearly Shares OutstandingAPLT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
APLT Yearly Total Debt VS Total AssetsAPLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -18.47, we must say that APLT is in the distress zone and has some risk of bankruptcy.
APLT has a Altman-Z score of -18.47. This is amonst the worse of the industry: APLT underperforms 82.92% of its industry peers.
There is no outstanding debt for APLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.47
ROIC/WACCN/A
WACCN/A
APLT Yearly LT Debt VS Equity VS FCFAPLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 3.00 indicates that APLT has no problem at all paying its short term obligations.
With a Current ratio value of 3.00, APLT is not doing good in the industry: 64.59% of the companies in the same industry are doing better.
APLT has a Quick Ratio of 3.00. This indicates that APLT is financially healthy and has no problem in meeting its short term obligations.
APLT's Quick ratio of 3.00 is on the low side compared to the rest of the industry. APLT is outperformed by 62.99% of its industry peers.
Industry RankSector Rank
Current Ratio 3
Quick Ratio 3
APLT Yearly Current Assets VS Current LiabilitesAPLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 84.86% over the past year.
Looking at the last year, APLT shows a very negative growth in Revenue. The Revenue has decreased by -97.39% in the last year.
EPS 1Y (TTM)84.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.61%
Revenue 1Y (TTM)-97.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, APLT will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.58% on average per year.
APLT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 226.65% yearly.
EPS Next Y27.07%
EPS Next 2Y19%
EPS Next 3Y16.61%
EPS Next 5Y14.58%
Revenue Next Year315.91%
Revenue Next 2Y669.57%
Revenue Next 3Y406.87%
Revenue Next 5Y226.65%

3.3 Evolution

APLT Yearly Revenue VS EstimatesAPLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
APLT Yearly EPS VS EstimatesAPLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APLT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLT Price Earnings VS Forward Price EarningsAPLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLT Per share dataAPLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

APLT's earnings are expected to grow with 16.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19%
EPS Next 3Y16.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPLIED THERAPEUTICS INC

NASDAQ:APLT (7/11/2025, 8:00:00 PM)

After market: 0.404 -0.01 (-2.39%)

0.4139

0 (-0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners82.48%
Inst Owner Change0%
Ins Owners1.56%
Ins Owner Change11.47%
Market Cap58.60M
Analysts80
Price Target2.93 (607.9%)
Short Float %15.94%
Short Ratio8.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)152.44%
Min EPS beat(2)22.6%
Max EPS beat(2)282.27%
EPS beat(4)3
Avg EPS beat(4)54.75%
Min EPS beat(4)-197.84%
Max EPS beat(4)282.27%
EPS beat(8)3
Avg EPS beat(8)-31.7%
EPS beat(12)7
Avg EPS beat(12)-10.6%
EPS beat(16)10
Avg EPS beat(16)-5.63%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.69%
EPS NQ rev (1m)5.2%
EPS NQ rev (3m)13.82%
EPS NY rev (1m)14.63%
EPS NY rev (3m)7.37%
Revenue NQ rev (1m)-66.67%
Revenue NQ rev (3m)-65.45%
Revenue NY rev (1m)-72.4%
Revenue NY rev (3m)-83.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 220.3
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.46%
ROE -118.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-185.04%
ROA(5y)-152.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3
Quick Ratio 3
Altman-Z -18.47
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.61%
EPS Next Y27.07%
EPS Next 2Y19%
EPS Next 3Y16.61%
EPS Next 5Y14.58%
Revenue 1Y (TTM)-97.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year315.91%
Revenue Next 2Y669.57%
Revenue Next 3Y406.87%
Revenue Next 5Y226.65%
EBIT growth 1Y8.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-54.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54.99%
OCF growth 3YN/A
OCF growth 5YN/A